Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenabasum - Corbus Pharmaceuticals

Drug Profile

Lenabasum - Corbus Pharmaceuticals

Alternative Names: Ajulemic acid; Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Resunab

Latest Information Update: 01 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antidotes; Antifibrotics; Antirheumatics; Antispastics; Cannabinoids; Carboxylic acids; Non-opioid analgesics; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Systemic scleroderma; Dermatomyositis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic lupus erythematosus

Highest Development Phases

  • Discontinued Cystic fibrosis; Dermatomyositis; Inflammation; Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning; Pulmonary fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

  • 10 Nov 2023 Updated efficacy data from the phase III RESOLVE-1 trial in Systemic sclerosis presented at the ACR Convergence 2023 (ACR-ARP-2023)
  • 31 Mar 2023 Discontinued - Phase-III for Dermatomyositis in United Kingdom, Sweden, Poland, South Korea, Italy, Japan, Germany, Czech Republic, Canada, Spain, Hungary, Bulgaria, USA (PO) prior to March 2023
  • 31 Mar 2023 Discontinued - Phase-III for Systemic scleroderma in Israel, Japan, South Korea, USA, Australia, Canada, Netherlands, United Kingdom, Germany, Poland, Spain, Switzerland, Italy (PO) prior to March 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top